Anti-fungal Agents Market Booming in Middle East and Africa Region with Healthy CAGR by 2022 | with Novartis AG, Pfizer, Inc., Sanofi-Aventis, Merck & Co., Inc., Enzon Pharmaceuticals, Inc., Bayer AG, etc

The Middle East and Africa Anti-fungal Agents Market has been evaluated as a growing market and it is expected that the market will grow at a moderate CAGR in future. The Middle East and Africa Anti-fungal agents market is expected to grow with CAGR of ~3.5% during the forecast period. The growth will be primary channeled by the need of unmet medical needs, rising incomes of the population and the high prevalence of fungal infection in Africa. Environmental factors such as high humidity and temperature along with the rich biodiversity of Africa will positively affect the market growth of anti-fungal agents.

The market drivers include rising prevalence of fungal infections, rising awareness, rise of immunity deficient population such as geriatrics, rise in exposure to infectious agents due to environmental factors such as pollution especially by particulates and agriculture residues and climatic conditions such as humidity and temperature, occupational hazards such as Jock itch, crowding etc. Growth of fungal infection due to off label use of broad spectrum antibiotics is a prime factor for the growing market for anti-fungal agents.

To Get Sample Report visit https://www.marketresearchfuture.com/sample_request/2582

The market restraints include rising resistance to anti-fungal agents, use of air filters and air conditioning, excellent spectrum and efficacy of Azole class of anti-fungal agents, loss of patents and genericitization etc. Competition by generics is exceptionally strong and generics account for roughly 50% of total sales for anti-fungal agents. The market penetration is very easy as there has been loss of patents of block buster drugs. Over the counter drugs are an important reasons for the growth of anti-fungal agents market. The Middle East and Africa anti-fungal agents market is led by Azoles followed by Echinocandins. The Azole class is represented in the market by agents such as Noxafil, Vfend, and Diflucan.

Taking all factors into consideration, we expect the Middle East and Africa anti-fungal agents market to reach around $2.85 billion by 2022 from $2.32 billion in 2015, by the end of the forecast period at a CAGR of ~3.5%.

Key Players for Global Middle East and Africa Anti-fungal Agents Market

Market Research Future (MRFR) recognizes the following companies as the key players in Middle East and Africa Anti-fungal Agents Market: There are plenty of large and small market players which operate in this market all over the globe.

The major participants of this market are: Novartis AG, Pfizer, Inc., Sanofi-Aventis, Merck & Co., Inc., Enzon Pharmaceuticals, Inc., Bayer AG, Astellas Pharma, Inc., GlaxoSmithKline plc, Abbott, Sigma-Aldrich and others

Segments for Global Middle East and Africa Anti-fungal Agents Market

Middle East and Africa anti-fungal agents market has been segmented on the basis of therapeutic indication which comprises into aspergillosis, dermatophytosis, candidiasis and others. On the basis of drug class; market is segmented into azoles, pyrimidines, echinocandins, polyenes, allylamines, and others. On the basis of route of administration; market is segmented into oral, local and others.

Regional Analysis for Global Middle East and Africa Anti-fungal Agents Market

Depending on geographic region, anti-fungal agents market is segmented into following countries: UAE, Egypt, Saudi Arabia, Kuwait, Qatar and Oman. UAE is the largest market followed by Egypt. However the future market will be led by the poor developed parts of Africa due to large unmet needs and the seasonal climatic conditions of Africa. The eastern parts of Africa is expected to have greater market share as compared to the hot and dry western coast.

To Browse Complete Report @ https://www.marketresearchfuture.com/reports/mea-anti-fungal-agents-market-2582

Some Brief Table of Contents of Report

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

TOC Continued…

List Of Tables

TABLE 1 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, 2013-2022 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY THERAPEUTIC INDICATION, 2013-2022 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY DRUG CLASS, 2013-2022 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2013-2022 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY REGION, 2013-2022 (USD MILLION)

List Of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY THERAPEUTIC INDICATION

FIGURE 4 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY DRUG CLASS

FIGURE 5 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 6 MIDDLE EAST AND AFRICA ANTI-FUNGAL AGENTS MARKET, BY REGION

Continued...

Do You Have Specific Requirement? Ask To Our Experts https://www.marketresearchfuture.com/enquiry/2582

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.